BioSpace News Archive

PMB, a subsidiary of the ALCEN group, is proud to announce the launch of FLASHKNiFE, the FLASH radiotherapy system dedicated to clinical trials.

CEL-SCI Corporation (NYSE American: CVM) , a Phase 3 cancer immunotherapy company, announced today that Geert Kersten, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25, 2020 at 12:30 p.m. ET. A live audio webcast of the chat will be available at http://wsw.com/webcast/hcw9/cvm or on the Investor Relations section of CEL-SCI’s website

Okami Medical Inc., announced today the close of a Series D financing totaling $7.2 million. The financing was led by U.S. Venture Partners and was joined by members of Okami’s board of directors and medical device industry veterans.

Grant funding from the Richard King Mellon Foundation supports unique collaboration aimed at providing health care workers an additional layer of protection from infectious disease

According to Coherent Market Insights, the global rigid knee braces market is estimated to be valued at US$ 836.6 million in 2020 and is expected to exhibit a CAGR of 4.2% during the forecast period (2020-2027). Key Trends and Analysis: The global rigid knee braces market is expected to witness significant growth, owing to increasing launch of rigid knee braces. For instance, in March 2018, Ossur announced t

Simcha Therapeutics, a biotechnology company developing first-in-class biologic drugs that modulate powerful cytokine pathways, launched today with $25 million in Series A financing and a mission to harness the precision and power of the immune system through the use of directed evolution.

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

The Association for the Accreditation of Human Research Protection Programs announced that it has awarded full accreditation to Western Michigan University Homer Stryker M.D. School of Medicine.

NantKwest, Inc., a clinical-stage, natural killer cell-based therapeutics company, announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that it has commenced an underwritten public offering of $125.0 million of its common stock.